Adaptimmune Therapeutics plc
ADAP
$0.0585
$0.00142.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.09M | 179.64M | 178.03M | 175.04M | 141.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.09M | 179.64M | 178.03M | 175.04M | 141.46M |
| Cost of Revenue | 128.69M | 143.66M | 149.13M | 143.17M | 146.65M |
| Gross Profit | -63.61M | 35.98M | 28.90M | 31.87M | -5.19M |
| SG&A Expenses | 89.95M | 90.55M | 88.66M | 69.63M | 64.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.64M | 234.20M | 237.79M | 212.79M | 211.16M |
| Operating Income | -153.55M | -54.57M | -59.76M | -37.75M | -69.70M |
| Income Before Tax | -166.05M | -66.27M | -67.24M | -43.29M | -71.42M |
| Income Tax Expenses | 3.71M | 3.63M | 3.58M | 1.23M | 1.08M |
| Earnings from Continuing Operations | -169.76 | -69.90 | -70.81 | -44.52 | -72.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.76M | -69.90M | -70.81M | -44.52M | -72.50M |
| EBIT | -153.55M | -54.57M | -59.76M | -37.75M | -69.70M |
| EBITDA | -142.93M | -43.70M | -48.53M | -26.49M | -58.37M |
| EPS Basic | -3.95 | -1.63 | -1.72 | -1.25 | -2.05 |
| Normalized Basic EPS | -0.38 | -0.14 | -0.15 | -0.11 | -0.19 |
| EPS Diluted | -4.10 | -1.94 | -2.03 | -1.44 | -2.24 |
| Normalized Diluted EPS | -0.38 | -0.14 | -0.15 | -0.11 | -0.19 |
| Average Basic Shares Outstanding | 1.03B | 1.02B | 1.01B | 980.34M | 950.88M |
| Average Diluted Shares Outstanding | 172.13M | 171.43M | 168.91M | 164.10M | 159.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |